Cargando…

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells

While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders may eventually become resistant. Therefore, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Yaxun, Wang, Min, Sang, Xiaolin, Liu, Pixu, Gao, Jingchun, Jiang, Kui, Cheng, Hailing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825372/ https://www.ncbi.nlm.nih.gov/pubmed/35155204 http://dx.doi.org/10.3389/fonc.2021.812264

Ejemplares similares

Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures
por: Chan, Daniel K, et al.
Publicado: (2012)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
por: Yi, Jingyan, et al.
Publicado: (2019)

Dietary Isothiocyanates, Sulforaphane and 2-Phenethyl Isothiocyanate, Effectively Impair Vibrio cholerae Virulence
por: Krause, Klaudyna, et al.
Publicado: (2021)

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
por: Sahin, Irem Durmaz, et al.
Publicado: (2019)

Phenethyl isothiocyanate activates leptin signaling and decreases food intake
por: Yagi, Miho, et al.
Publicado: (2018)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer
por: Dai, Danian, et al.
Publicado: (2021)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
por: Bound, Nirashaa T., et al.
Publicado: (2022)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

BAG3 Protein Is Involved in Endothelial Cell Response to Phenethyl Isothiocyanate
por: Franceschelli, Silvia, et al.
Publicado: (2018)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

Dietary Phenethyl Isothiocyanate Alters Gene Expression in Human Breast Cancer Cells
por: Moon, Young Jin, et al.
Publicado: (2011)

Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models
por: Gupta, Parul, et al.
Publicado: (2012)

Nrf2 Knockout Attenuates the Anti-Inflammatory Effects of Phenethyl Isothiocyanate and Curcumin
por: Boyanapalli, Sarandeep S. S., et al.
Publicado: (2014)

Dietary Phenethyl Isothiocyanate Protects Mice from Colitis Associated Colon Cancer
por: Liu, Yi, et al.
Publicado: (2017)

Phenethyl Isothiocyanate Inhibits In Vivo Growth of Xenograft Tumors of Human Glioblastoma Cells
por: Chou, Yu-Cheng, et al.
Publicado: (2018)

Various modes of action of dietary phytochemicals, sulforaphane and phenethyl isothiocyanate, on pathogenic bacteria
por: Nowicki, Dariusz, et al.
Publicado: (2019)

Phenethyl Isothiocyanate-Containing Carbomer Gel for Use against Squamous Cell Carcinoma
por: Osipitan, Ositomiwa O., et al.
Publicado: (2021)

Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer
por: Koc, Zeynep C., et al.
Publicado: (2023)

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
por: Wang, Dong, et al.
Publicado: (2016)

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
por: Horton, Julie K., et al.
Publicado: (2013)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Advances in Tumor Screening, Imaging, and Avatar Technologies for High-Grade Serous Ovarian Cancer
por: Ohman, Anders W., et al.
Publicado: (2014)

High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer
por: Song, Li, et al.
Publicado: (2019)

Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models
por: Heredia-Soto, Victoria, et al.
Publicado: (2022)

Phenethyl Isothiocyanate, a Dual Activator of Transcription Factors NRF2 and HSF1
por: Dayalan Naidu, Sharadha, et al.
Publicado: (2018)

Phenethyl Isothiocyanate-Conjugated Chitosan Oligosaccharide Nanophotosensitizers for Photodynamic Treatment of Human Cancer Cells
por: Bae, Inho, et al.
Publicado: (2022)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer
por: Krajnak, Slavomir, et al.
Publicado: (2021)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer
por: Zhang, Jie, et al.
Publicado: (2022)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Stage, treatment and survival of low‐grade serous ovarian carcinoma in the Netherlands: A nationwide study
por: De Decker, Koen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m3pktr87ir48um4c598j569die